Role of gabapentin enacarbil XR in restless legs syndrome
Gabapentin enacarbil XR is a new extended-release formulation which attempts to overcome the reduced efficacy of shorter-acting gabapentin, with sustained delivery over a 24-hour period. It is a gabapentin prodrug which is efficiently and rapidly converted to gabapentin during active transport throu...
Main Authors: | Sivam, Sheila, Yee, Brendon J |
---|---|
Format: | Online |
Language: | English |
Published: |
Dove Medical Press
2012
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3346203/ |
Similar Items
-
Gabapentin Enacarbil: Pharmacotherapy of Restless Legs Syndrome
by: Jones, Ruth, et al.
Published: (2010) -
Review of the Treatment of Restless Legs Syndrome: Focus on Gabapentin Enacarbil
by: Burke, Rachel A., et al.
Published: (2012) -
Gabapentin enacarbil for the treatment of moderate to severe primary restless legs syndrome (Willis-Ekbom disease): 600 or 1,200 mg dose?
by: Kume, Akito
Published: (2014) -
Gabapentin enacarbil extended release for the treatment of postherpetic neuralgia in adults
by: Thomas, Ben M, et al.
Published: (2013) -
Effect of prior exposure to dopamine agonists on treatment with gabapentin enacarbil in adults with moderate-to-severe primary restless legs syndrome: pooled analyses from 3 randomized trials
by: Ondo, William G, et al.
Published: (2015)